Abstract
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
| Original language | English (US) |
|---|---|
| Article number | 16011 |
| Number of pages | 1 |
| Journal | Molecular Therapy - Oncolytics |
| Volume | 3 |
| DOIs | |
| State | Published - Apr 20 2016 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Cancer Research
- Pharmacology (medical)
Cite this
Toxicity and management in CAR T-cell therapy. / Bonifant, Challice; Jackson, Hollie J.; Brentjens, Renier J.; Curran, Kevin J.
In: Molecular Therapy - Oncolytics, Vol. 3, 16011, 20.04.2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Toxicity and management in CAR T-cell therapy
AU - Bonifant, Challice
AU - Jackson, Hollie J.
AU - Brentjens, Renier J.
AU - Curran, Kevin J.
PY - 2016/4/20
Y1 - 2016/4/20
N2 - T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
AB - T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
UR - http://www.scopus.com/inward/record.url?scp=84969244099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969244099&partnerID=8YFLogxK
U2 - 10.1038/mto.2016.11
DO - 10.1038/mto.2016.11
M3 - Review article
AN - SCOPUS:84969244099
VL - 3
JO - Molecular Therapy - Oncolytics
JF - Molecular Therapy - Oncolytics
SN - 2372-7705
M1 - 16011
ER -